Blood

Vol. 145, Issue 9 Issue 9 2025
15
Articles

Articles in this Issue

Competition for CD19 binding may accelerate CAR efficacy

Alexandre V. Hirayama, Marie Bleakley Feb 27, 2025 pp. 902-903 10.1182/blood.2024027469

Deficiency of neutrophil gelatinase-associated lipocalin elicits a hemophilia-like bleeding and clotting disorder in mice

Min Xue, Shaoying Wang, Changjiang Li et al. Feb 27, 2025 pp. 975-987 10.1182/blood.2024026476

Abstract Coagulation is related to inflammation, but the key pathway, especially innate immune system and coagulation regulation, is not well understood and need to be further explor...

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Dan T. Vogl, Shebli Atrash, Sarah A. Holstein et al. Feb 27, 2025 pp. 944-955 10.1182/blood.2024026124

Abstract Interferon alfa has activity against multiple myeloma (MM). Modakafusp alfa is an immunocytokine comprising 2 attenuated interferon alfa-2b molecules and an anti-CD38 immuno...

Monitoring CH: time to move beyond VAF?

Lachelle D. Weeks Feb 27, 2025 pp. 907-908 10.1182/blood.2024027472

Novel treatment strategies for chronic myeloid leukemia

Nataly Cruz-Rodriguez, Michael W. Deininger Feb 27, 2025 pp. 931-943 10.1182/blood.2024026312

Abstract Starting with imatinib, tyrosine kinase inhibitors (TKIs) have turned chronic myeloid leukemia (CML) from a lethal blood cancer into a chronic condition. As patients with ac...

Hypercalcemia in MGUS: keep the differential diagnosis broad

Hira Mian, Alissa Visram Feb 27, 2025 pp. 904-905 10.1182/blood.2024027928

NGAL: a new link between thrombosis and hemostasis

Badr Kilani, Konstantin Stark Feb 27, 2025 pp. 905-906 10.1182/blood.2024027586

Introduction to a series of reflections on a quarter century of TKIs for CML

Brian J. Druker Feb 27, 2025 pp. 909-909 10.1182/blood.2024026515

This Review Series highlights the transformative impact of tyrosine kinase inhibitors (TKIs) on therapy for chronic myeloid leukemia (CML) in the last 25 years. Brian J. Druker introduces the series b...

Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis

Seung Kwon Koh, Hyojin Kim, Bohwa Han et al. Feb 27, 2025 pp. 956-969 10.1182/blood.2024025673

Abstract Anti-CD19 chimeric antigen receptor (CAR)–engineered T and natural killer (NK) cell therapies have revolutionized the treatment of B-cell malignancies, but challenges includ...

Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia

François Guilhot, Rüdiger Hehlmann Feb 27, 2025 pp. 910-920 10.1182/blood.2024026311

Abstract Long-term outcomes with tyrosine kinase inhibitors (TKIs) show that their impact on chronic myeloid leukemia (CML) is sustained as shown by 13 studies with 5- to 14-year-fol...

Novel interferon-based antimyeloma activity

Arthur Bobin, Xavier Leleu Feb 27, 2025 pp. 901-902 10.1182/blood.2024027417

Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening study

Ástrún Helga Jónsdóttir, Helga Ágústa Sigurjónsdóttir, Sigrún Thorsteinsdóttir et al. Feb 27, 2025 pp. 970-974 10.1182/blood.2024025624

Abstract Hypercalcemia in monoclonal gammopathy of undetermined significance (MGUS) presents a clinical challenge because it may indicate progression to multiple myeloma (MM) but cou...

The evolution of treatment-free remission

Timothy P. Hughes, Agnes S. M. Yong, David M. Ross Feb 27, 2025 pp. 921-930 10.1182/blood.2024026310

Abstract One of the most remarkable achievements of the tyrosine kinase inhibitor (TKI) era has been the capacity to induce deep molecular remissions that are sustainable off therapy...

Distinctive morphologic finding of multifocal perifollicular concentric granulomas in a lymph node with IgG4 plasmacytosis

Julia Wang, Annapurna Saksena Feb 27, 2025 pp. 993-993 10.1182/blood.2024027289

Methylation sequencing enhances interpretation of clonal hematopoiesis dynamics

Alyssa C. Parker, Joseph C. Van Amburg, J. Brett Heimlich et al. Feb 27, 2025 pp. 988-992 10.1182/blood.2024026555

Abstract We have developed a cost-effective DNA methylation sequencing assay to improve monitoring of clonal hematopoiesis. By inferring cell-type proportions, this method enhances i...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page